Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 18/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 9/20 | 1.00 |
| ▸ | KDR | P35968 | 8/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.93 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20158959 | 0.96 | TGFBR1 (1.00) | TGFBR1MAPK14KDRRIPK2THRB | |
| SCHEMBL20158913 | 0.96 | TGFBR1 (1.00) | TGFBR1MAPK14KDRRIPK2THRB | |
| SCHEMBL20158915 | 0.92 | TGFBR1 (0.85) | TGFBR1MAPK14KDRRIPK2THRB | |
| SCHEMBL21315502 | 0.91 | TGFBR1 (0.82) | TGFBR1MAPK14KDRRIPK2THRB | |
| SCHEMBL21325558 | 0.91 | TGFBR1 (0.82) | TGFBR1MAPK14KDRRIPK2THRB | |
| SCHEMBL20158957 | 0.91 | TGFBR1 (0.82) | TGFBR1MAPK14KDRRIPK2THRB | |
| SCHEMBL21315503 | 0.91 | TGFBR1 (0.82) | TGFBR1MAPK14KDRRIPK2THRB | |
| SCHEMBL20158910 | 0.91 | TGFBR1 (0.82) | TGFBR1MAPK14KDRRIPK2THRB | |
| SCHEMBL21315498 | 0.90 | TGFBR1 (1.00) | TGFBR1MAPK14KDRRIPK2THRB | |
| SCHEMBL20158955 | 0.90 | TGFBR1 (1.00) | TGFBR1MAPK14KDRRIPK2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108779100-B | 3, 4-dipyridyl pyrazole derivatives, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2021-11-16 | — | — | CN | disclosed |
| US-10899741-B2 | 3,4-bipyridyl pyrazole derivative, and preparation method therefor and medical application thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-01-26 | — | — | US | disclosed |
| EP-3539957-A1 | 3,4-BIPYRIDYL PYRAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL APPLICATION THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2019-09-18 | — | — | EP | disclosed |
| EP-3539957-A1 | 3,4-BIPYRIDYL PYRAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL APPLICATION THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2019-09-18 | — | — | EP | disclosed |
| US-20190270724-A1 | 3,4-BIPYRIDYL PYRAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL APPLICATION THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-09-05 | — | — | US | disclosed |
| US-20190270724-A1 | 3,4-BIPYRIDYL PYRAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL APPLICATION THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-09-05 | — | — | US | disclosed |
| WO-2018086609-A1 | 3,4-BIPYRIDYL PYRAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL APPLICATION THEREOF | 江苏恒瑞医药股份有限公司 | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10899741-B2 | 3,4-bipyridyl pyrazole derivative, and preparation method therefor and medical application thereof | TGFBR1, TGFB1, TGFB2 | TGFBR1 1/4885MAPK14 521/4885KDR 306/4885 |
| US-20190270724-A1 | 3,4-BIPYRIDYL PYRAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL APPLICATION THEREOF | TGFBR1, TGFB1, TGFB2 | TGFBR1 1/4885MAPK14 521/4885KDR 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.